Tue10212014

Last update 10:52:30 AM EST

AeroCare and MergeWorthRx Corp to Merge

AeroCare and MergeWorthRx Corp to Merge

Special purpose acquisition company, MergeWort...

FDA Approves Two Breakthrough Idiopathic Pulmonary Fibrosis Drugs

FDA Approves Two Breakthrough Idiopathic Pulmonary Fibrosis Drugs

The US Food and Drug Administration (FDA) rece...

AbbVie's Board Recommends Against the $55 Billion Acquisition of Shire

AbbVie's Board Recommends Against the $55 Billion Acquisition of Shire

Chicago-based AbbVie Inc. announced that its Boa...

John D. Petersen of AstraZeneca Joins NASP Board of Directors

John D. Petersen of AstraZeneca Joins NASP Board of Directors

TAMPA, FL, October 16, 2014 —The Nationa...

FDA Grants Priority Review to Eisai's Cancer Drug Lenvatinib

FDA Grants Priority Review to Eisai's Cancer Drug Lenvatinib

Today, Eisai announced that its anticancer age...

NICE Issues Negative Guidance for Celgene's Multiple Myeloma Drug

NICE Issues Negative Guidance for Celgene's Multiple Myeloma Drug

The UK’s cost watchdog rejected funding for Celg...

Regeneron's Eylea Beats Avastin and Lucentis in Comparative Study

Regeneron's Eylea Beats Avastin and Lucentis in Comparative Study

Regeneron Pharmaceuticals, Inc. recently announced that its Eylea (afliberce...

Celgene's Experimental Crohn's Disease Drug Demonstrates Positive Mid-Stage Results

Celgene's Experimental Crohn's Disease Drug Demonstrates Positive Mid-Stage Results

Today, Celgene presented a first detailed look at its recently acquired, exper...

FDA Approves Two Breakthrough Idiopathic Pulmonary Fibrosis Drugs

FDA Approves Two Breakthrough Idiopathic Pulmonary Fibrosis Drugs

The US Food and Drug Administration (FDA) recently approved two new drugs fo...

Imbruvica sNDA Submitted to the FDA for Treatment of Rare Blood Cancer

Imbruvica sNDA Submitted to the FDA for Treatment of Rare Blood Cancer

Today, Janssen Research & Development, LLC announced that its strategic pa...

Personalized Cellular Therapy Achieves Promising Results in Acute Lymphoblastic Leukemia Patients

Personalized Cellular Therapy Achieves Promising Results in Acute Lymphoblastic Leukemia Patients

PHILADELPHIA – Ninety percent of children and adults with acute lymphoblastic ...

FDA Grants Priority Review to Eisai's Cancer Drug Lenvatinib

FDA Grants Priority Review to Eisai's Cancer Drug Lenvatinib

Today, Eisai announced that its anticancer agent lenvatinib received Priorit...

NICE Issues Negative Guidance for Celgene's Multiple Myeloma Drug

NICE Issues Negative Guidance for Celgene's Multiple Myeloma Drug

The UK’s cost watchdog rejected funding for Celgene’s Imnovid (pomalidomide) f...

Allogeneic Transplantation May Lead to Sustained Remissions in Multiple Myeloma Patients

Allogeneic Transplantation May Lead to Sustained Remissions in Multiple Myeloma Patients

Allogeneic transplantation for multiple myeloma can lead to sustained remiss...

Navidea's Lymphoseek Receives Expanded Approval from the FDA

Navidea's Lymphoseek Receives Expanded Approval from the FDA

The US Food and Drug Administration (FDA) has approved the expanded use of Nav...

Genentech Launches $1.15 Billion Cancer Collaboration with NewLink Genetics

Genentech Launches $1.15 Billion Cancer Collaboration with NewLink Genetics

NewLink Genetics has agreed to license its early-stage cancer program to Gen...

AeroCare and MergeWorthRx Corp to Merge

AeroCare and MergeWorthRx Corp to Merge

Special purpose acquisition company, MergeWorthRx Corp. recently announced t...

AbbVie's Board Recommends Against the $55 Billion Acquisition of Shire

AbbVie's Board Recommends Against the $55 Billion Acquisition of Shire

Chicago-based AbbVie Inc. announced that its Board of Directors has decided to...

John D. Petersen of AstraZeneca Joins NASP Board of Directors

John D. Petersen of AstraZeneca Joins NASP Board of Directors

TAMPA, FL, October 16, 2014 —The National Association of Specialty Pha...

BD Acquires GenCell Biosystems

BD Acquires GenCell Biosystems

Global medical technology company Becton, Dickinson and Company (BD) recentl...

FDA Committee Unanimously Recommends Approval of Novartis' Psoriasis Candidate

FDA Committee Unanimously Recommends Approval of Novartis' Psoriasis Candidate

An advisory panel to the US Food and Drug Administration (FDA) voted unanimo...